A new Mayo Clinic study found that an off-the-shelf dual-antibody therapy generates deep and durable responses in extramedullary multiple myeloma. In a trial of 90 patients, 79% responded to treatment, with nearly two-thirds maintaining disease control at one year.
A new study by Mayo Clinic researchers found that using digital check-ins and a remote care team can help patients manage symptoms before they reach a crisis point. The trial showed that the automated surveys and responses built into the electronic health record made care more efficient and improved patients' symptoms.
Researchers developed a new 3D surface scanning approach for precise brain surgery, outperforming CT scans in accuracy. The system eliminates radiation exposure and provides real-time guidance to surgeons.
Mayo Clinic researchers have found several previously unknown genetic and cellular processes that occur in lung adenocarcinoma tumors responding well to immunotherapy. The study identified markers that may predict a positive response to immunotherapy, including the presence of senescent tumor cells and loss of the PRKCI gene.
Researchers at Mayo Clinic have developed a new approach to treating drug-resistant epilepsy by mapping each patient's unique brain wave patterns. This method enables physicians to target the precise area in the brain where stimulation is most effective, moving beyond traditional one-size-fits-all treatment.
A Mayo Clinic study found that nearly 90% of people with the inherited condition familial hypercholesterolemia would not have been flagged for standard genetic testing. This condition can cause dangerously high cholesterol and early heart disease, making it highly treatable yet often undiagnosed.
Researchers create new prediction model combining age, sex, genetic risk, and brain amyloid levels to calculate lifetime risk of developing memory problems. The study, published in The Lancet Neurology, found women have a higher lifetime risk than men, with the common APOE ε4 variant increasing risk.
Researchers created an AI algorithm that can identify obstructive sleep apnea (OSA) using ECG test results, making it faster and cheaper to spot the condition. The innovation reveals a higher visibility of OSA on ECG in females compared to males, suggesting they may suffer more cardiovascular damage.
The new approach uses lab-grown heart tissue made from reprogrammed adult stem cells, delivered through a tiny incision. In preclinical testing, the stem cell patch restored heart function and improved healing, offering a new way to repair damaged hearts.
Mayo Clinic's new platform provides access to its data-driven expertise, clinical knowledge, and AI insights to healthcare organizations worldwide. The program helps navigate the complex AI landscape in healthcare and implement solutions to improve patient outcomes.
HealthLocator gathers national quality data to compare hospitals based on performance and provide informed care choices. The tool is offered as a free public service by Mayo Clinic, using evidence-based measures to rate over 5,000 U.S. hospitals.
Researchers at Mayo Clinic have found a way to enhance the body's 'first responder' cells, which can boost standard immunotherapies for cancer. By targeting these myeloid cells, it may be possible to improve treatments that interfere with immune suppressive proteins PD-1 and PD-L1.
A Mayo Clinic study of nearly 5,000 midlife women found that over three-quarters experienced menopause symptoms, yet only one in four received treatment. The study highlights the importance of healthcare professionals identifying and managing menopause symptoms to improve women's health and quality of life.
Researchers at Mayo Clinic have developed a new technique to identify senescent cells using aptamers, which can potentially lead to targeted therapies. The study found several rare aptamers that bind specifically to fibronectin on the surface of mouse cells, offering a promising approach for characterizing and treating senescent cells.
A new study led by Mayo Clinic researchers found that abemaciclib improves survival for people with high-risk, early-stage breast cancer. The drug reduced the risk of death by 15.8% compared to endocrine therapy alone among patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer.
A new genomic test can identify people with melanoma as being at low or high risk of cancer spreading to their lymph nodes. The test uses gene expression profiles from a tumor sample, eliminating the need for additional biopsies, and may help guide treatment decisions.
Researchers at the Mayo Clinic have found that platelet-rich plasma (PRP) treatment can significantly improve genitourinary syndrome of menopause (GSM) symptoms in breast cancer survivors. After six months, GSM symptoms such as sexual function, urinary symptoms and quality of life improved, even among those taking estrogen blockers.
Researchers discovered a molecular circuit controlling AT2 cell fate plasticity, which could guide regenerative therapies for chronic lung diseases. The discovery highlights potential new targets for regenerative medicine and may lead to earlier detection and prevention of organ failure.
Researchers identified KCTD10, a 'traffic controller' protein that shields DNA during cell division, potentially leading to new cancer therapies. The discovery could target cancer cells where DNA replication and transcription processes malfunction.
Mayo Clinic has been awarded up to $40 million by ARPA-H to develop new ways to monitor and improve air quality in real-time, enhancing patient care. The Hospital Air Quality (HAIQU) project will introduce cutting-edge biosensors, AI, and smart air filtration systems in emergency departments across Mayo's campuses.
A recent study published in Radiology found that adding molecular breast imaging to a 3D mammogram improved the ability to detect cancer in dense breast tissue. The combined test detected more cancerous tissue than either technique alone, increasing cancer finds by over double.
Mayo Clinic has opened its fifth international office in Dubai, providing patient support services and connecting patients with global healthcare resources. The new office offers assistance with travel, lodging, billing, and insurance arrangements, as well as facilitating communication between patients and healthcare providers.
Mayo Clinic's new program enables biopharma companies to accelerate clinical development by providing access to de-identified data, advanced AI tools, and a global distribution network. This collaboration streamlines access to Mayo Clinic's world-class research expertise, allowing companies to move efficiently from discovery to delivery.
Researchers at Mayo Clinic identified a genetic factor contributing to severe liver damage after chemotherapy for colorectal cancer patients. A specific gene variant, PNPLA3, was linked to increased risk of liver injury.
Saudi German Health has expanded its partnership with Mayo Clinic to become the largest group of Mayo Clinic Care Network members in the region. The partnership aims to enhance patient outcomes and quality of care through clinical transformation programs, sharing world-class expertise and resources.
Researchers at Mayo Clinic found that transplanting patients' own stem cells into their veins can help prevent inflammation and vein narrowing in patients with end-stage kidney disease. This could extend the time before dialysis is required, reducing healthcare costs and improving patient outcomes.
Researchers developed AI tools that use machine learning and natural language processing to extract details from doctors' notes. The tools detected a high-risk asthma subtype that makes some children more vulnerable to acute respiratory infections and asthma exacerbation.
Mayo Clinic researchers developed a genetic test that can predict how people will respond to weight loss medications. The test estimates an individual's calories to satiation, linking it to treatment success and providing personalized estimates of expected satiation threshold.
A new Mayo Clinic study found that many heart attacks in people under 65 are caused by factors other than clogged arteries, particularly in women. The study revealed that spontaneous coronary artery dissection (SCAD), embolism, and stress-related triggers accounted for over half of heart attacks in women under age 65.
A new genetic test developed at Mayo Clinic is redefining how clinicians diagnose and manage hereditary pancreatitis. The test includes nine genes and uses whole exome sequencing to analyze coding regions, providing comprehensive analysis of disease-causing genes.
Mayo Clinic researchers found that excessive alcohol alters an enzyme that recycles damaged proteins, leading to the accumulation of fat in liver cells. The study suggests that targeting this enzyme could prevent or treat fatty liver disease.
A Mayo Clinic study shows that a shorter, less intense course of radiation and chemotherapy after minimally invasive surgery significantly reduces treatment-related side effects while maintaining high cure rates. The findings apply to intermediate-risk patients, with slightly better disease control in high-risk patients.
A new study identifies a genetic biomarker, telomerase reverse transcriptase (TERT), that can predict the aggressiveness of meningiomas. High TERT expression is linked to faster disease progression and poorer outcomes, even in low-grade tumors.
A new Mayo Clinic AI tool, UNISOM, has shown promising results in identifying early signs of clonal hematopoiesis of indeterminate potential (CHIP), a condition that raises the risk of leukemia and heart disease. The tool helps detect CHIP-related mutations in standard genetic datasets, opening new avenues for research and discovery.
Researchers found specialized immune cells, called stem-like T cells, that behave like young stem cells but instead spread disease. These immune cells were found in over 100 older patients with autoimmune diseases, such as giant cell arteritis.
Researchers at Mayo Clinic have developed a new tool called BACDAC to identify signs of genomic instability in cancer. The tool uses DNA sequencing to detect structural alterations in tumors, which can fuel aggressive growth and evade standard testing.
Researchers identified a sugar molecule called sialic acid that helps cancer cells evade the immune system. By engineering beta cells to produce this molecule, they found it possible to tolerate these cells and prevent their destruction. The study offers new hope for treating type 1 diabetes without immunosuppression.
Mayo Clinic has been ranked as the top hospital in the US for 36 consecutive years, with two of its hospitals earning high scores in various specialties. The organization attributes its success to its commitment to innovation, excellence, and patient care.
Mayo Clinic has deployed NVIDIA Blackwell infrastructure to accelerate pathomics, drug discovery, and precision medicine using generative AI. The new infrastructure enables faster pathology slide analysis and foundation model development, reducing work time from four weeks to one week.
Researchers found that CAR-T cells age and lose effectiveness due to premature senescence, a previously unrecognized mechanism of therapy failure. The discovery highlights the need for next-generation therapies with improved durability.
A new AI model developed by Mayo Clinic and Ultromics can detect cardiac amyloidosis, a rare and progressive type of heart failure, with high accuracy. The model was validated on a large patient population and outperformed traditional screening methods in identifying the disease.
Researchers at Mayo Clinic developed pioneering therapies to prevent organ rejection without the need for immunosuppression. A recent phase 3 clinical trial found that 75% of participants were able to stop taking immunosuppressive medications for more than two years, with some patients staying off medication for over three years.
A Mayo Clinic team developed an AI system that can automatically identify surgical incisions and flag signs of infection in patient-submitted photos. The model achieved high accuracy in detecting incisions and identifying infections, with potential to streamline communication between patients and their care teams.
The Hospital Internacional de Colombia has joined the Mayo Clinic Care Network, a group of vetted health organizations with access to Mayo Clinic's knowledge and expertise. The network aims to advance high-quality patient-centered care through innovation and collaboration.
The AI tool, StateViewer, helps clinicians identify brain activity patterns linked to nine types of dementia, including Alzheimer's disease, using a single scan. It enables clinicians to interpret brain scans nearly twice as fast and with up to three times greater accuracy than standard workflows.
The Mayo Clinic in Arizona has launched a new lung transplant program, providing patients with end-stage lung disease a second chance at life. The program offers world-class care to critically ill patients battling respiratory diseases such as COPD, and is supported by clinical innovation from across Mayo Clinic.
Mayo Clinic researchers have detected early, hidden changes in cells lining a patient's fallopian tubes, revealing signals that may point to the first signs of ovarian cancer. The study uses cutting-edge single-cell technologies to uncover developmental alterations in epithelial cells that signal high risk for lethal ovarian cancer.
Mayo Clinic has opened its first carbon ion therapy program in the Western Hemisphere, providing new hope for patients with treatment-resistant cancers. The Duan Family Building will also offer advanced proton therapy and other cancer treatments.
Researchers validated a blood test for diagnosing Alzheimer's disease with 95% sensitivity and 82% specificity. The test measures two proteins associated with amyloid plaque buildup, offering a more accessible and cost-effective alternative to invasive PET scans.
A new study found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer resulted in a 50% reduction in cancer recurrence and death compared to chemotherapy alone. The treatment combination showed significant benefits for patients with deficient DNA mismatch repair genetic makeup.